|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study显示文摘Background:Average postoperative follow-up intervals vary in patients undergoing hepatocellular carcinoma(HCC)resection because of limited evidence regarding the optimal interval.We aimed to compare the associations of long-versus short-interval follow-up with survival and recurrence in risk-stratified HCC patients.Methods:We performed a retrospective cohort study between 2007 and 2014.In total,1227 patients treated by curative resection of Barcelona Clinic Liver Cancer stage A or B HCC were stratified as having a low(n=865)or high(n=362)risk of early recurrence(within the first 2 years after resection)based on prognostic factors identified by the least absolute shrinkage and selection operation algorithm.Patients were further classified into long-interval(every 4-6 months)and short-interval(every 2-4 months)follow-up subgroups based on follow-up within 2 years after resection(low risk,long vs.short:n=390 vs.n=475;high-risk,long vs.short:n=149 vs.n=213).Results:The short-interval follow-up did not prolong overall survival in either the low-risk(hazard ratio[HR]=1.152;95%confidence interval[CI]0.720-1.843)or high-risk(HR=1.213;95%CI 0.702-2.094)patients.Early recurrence occurred in 401 patients.For high-risk patients,the short-interval follow-up subgroup exhibited smaller intrahepatic recurrence than did the long-interval group(2.6 vs.3.5 cm,respectively,P=0.045).However,no significant difference in the rate of Barcelona Clinic Liver Cancer stage 0/A recurrence was found between the long-and short-interval follow-up groups in either low-or high-risk patients(63.1%vs.68.2%,respectively,P=0.580;31.3%vs.41.5%,respec-tively,P=0.280).The rate of curative intent treatment for recurrence(34.5%vs.39.7%,respectively,P=0.430;14.6%vs.20.3%,respectively,P=0.388)was also similar between the follow-up groups for low-and high-risk patients.Conclusions:Shortening the postoperative follow-up interval from every 4-6 months to every 2-4 months within the first 2 years after resection did not increase the rate of curative intent treatment or prolong the overall survival of patients with Barcelona Clinic Liver Cancer stage A or B HCC. | Wei He Yun Zheng Ruhai Zou Jingxian Shen Junping Yang Jiliang Qiu Qiang Tao Wenwu Liu Zhiwen Yang Yuanping Zhang Binkui Li Yunfei Yuan | 2018 | Cancer Communications2018，38，1： | 2 |
| 2 | Overexpression of amplified in breast cancer 1 (AIB1) gene promotes lung adenocarcinoma aggressiveness in vitro and in vivo by upregulating C-X-C motif chemokine receptor 4显示文摘Background:We previously found that overexpression of the gene known as amplified in breast cancer 1(AIB1)was associated with lymph node metastasis and poor prognosis in patients with lung adenocarcinoma.However,the role of AIB1 in that malignancy remains unknown.The present study aimed to investigate the function of AIB1 in the process of lung adenocarcinoma cell metastasis.Methods:A series of in vivo and in vitro assays were performed to elucidate the function of AIB1,while real-time PCR and Western blotting were utilized to identify the potential downstream targets of AIB1 in the process of lung adenocarcinoma metastasis.Rescue experiments and in vitro assays were performed to investigate whether the invasive-ness of AIB1-induced lung adenocarcinoma was mediated by C-X-C motif chemokine receptor 4(CXCR4).Results:The ectopic overexpression of AIB1 in lung adenocarcinoma cells substantially enhanced cell migration and invasive abilities in vitro and tumor metastasis in vivo,whereas the depletion of AIB1 expression substantially inhibited lung adenocarcinoma cell migration and invasion.CXCR4 was identified as a potential downstream target of AIB1 in lung adenocarcinoma.The knockdown of AIB1 greatly reduced CXCR4 gene expression at both the transcription and protein levels,whereas the knockdown of CXCR4 in cells with AIB1 ectopic overexpression diminished AIB1-induced migration and invasion in vitro and tumor metastasis in vivo.Furthermore,we found a significant positive association between the expression of AIB1 and CXCR4 in lung adenocarcinoma patients(183 cases),and the co-overexpression of AIB1 and CXCR4 predicted the poorest prognosis.Conclusions:These findings suggest that AIB1 promotes the aggressiveness of lung adenocarcinoma in vitro and in vivo by upregulating CXCR4 and that it might be usable as a novel prognostic marker and/or therapeutic target for this disease. | Liru He Haixia Deng Shiliang Liu Jiewei Chen Binkui Li Chenyuan Wang Xin Wang Yiguo Jiang Ningfang Ma Mengzhong Liu Dan Xie | 2018 | Cancer Communications2018，38，1： | 2 |
| 3 | MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis显示文摘 | Binkui Li Pinzhu Huang Jiliang Qiu Yadi Liao Jian Hong Yunfei Yuan | 2014 | Medical Oncology2014，，10： | 1 |
| 4 | Efficacy and safety of thermal ablation in patients with liver metastases显示文摘 | Yingjun Liu Shengping Li Xiangbin Wan Yi Li Binkui Li Yaqi Zhang Yunfei Yuan Yun Zheng | 2013 | European Journal of Gastroenterology & Hepatology2013，，4： | 1 |
| 5 | Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy显示文摘 | Pinzhu Huang Jiliang Qiu Binkui Li Jian Hong Canliang Lu Li Wang Jianping Wang Yezhu Hu Weihua Jia Yunfei Yuan | 2011 | Clinical Biochemistry2011，，8： | 1 |
| 6 | 肝癌切除术后的长间隔与短间隔随访:一项回顾性队列研究显示文摘背景与目的由于缺乏证据证明肝细胞癌(hepatocellular carcinoma,HCC)切除术后的最佳随访间隔,术后患者接受随访的平均时间间隔不同。我们的目的是比较长间隔随访和短间隔随访与生存和复发的相关性在不同风险分层肝癌患者中的差异。方法我们在2007年至2014年期间进行了一项回顾性队列研究。共有1227例巴塞罗那临床肝癌分期A期或B期的患者接受了根治性切除术。根据最小绝对收缩和选择操作算法为基础的预后因素分析,我们将患者分层为有低风险(n=865)或高风险(n=362)早期复发(切除术后2年内)的2组。根据切除术后2年内的随访情况,患者进一步分为长间隔(每4–6个月)随访和短期间隔(每2–4个月)随访的亚组(低风险,长期vs.短期:n=390 vs. n=475;高风险,长期vs.短期:n=149 vs. n=213)。结果不管在低风险[风险比(hazard ratio,HR)=1.152;95%置信区间(confidenceinterval,CI):0.720–1.843]还是高风险(HR=1.213;95%CI:0.702–2.094)患者中,短间隔随访没有延长患者的总生存期。401例患者出现早期复发。在高风险患者中,与长间隔随访组相比,短间隔组肝内复发肿瘤较小(2.6 cm vs. 3.5 cm,P=0.045)。但是,对于巴塞罗临床肝癌分期0/A期,长间隔与短间隔随访不管在低风险还是高风险患者中复发率(63.1%vs. 68.2%,P=0.580;31.3%vs. 41.5%,P=0.280)差异均无统计学意义。类似的,根治性切除术后,长间隔或短间隔随访分别在低风险和高风险患者中的复发率(34.5%vs. 39.7%,P=0.430;14.6%vs. 20.3%,P=0.388)差异也均无统计学意义。结论对于巴塞罗那临床肝癌分期A期或B期的患者,在接受了根治性切除术后的前2年内,将随访时间从4–6月缩短为2–4个月并不能增加根治性切除术的成功率或延长患者生存时间。 | Wei He Yun Zheng Ruhai Zou Jingxian Shen Junping Yang Jiliang Qiu Qiang Tao Wenwu Liu Zhiwen Yang Yuanping Zhang Binkui Li Yunfei Yuan | 2018 | 癌症2018，37，12： | 0 |
| 7 | Dysregulation of PLOD2 Promotes Tumor Metastasis and Invasion in Hepatocellular Carcinoma显示文摘Background and Aims:Metastasis is a major factor associated with high recurrence and mortality in hepatocellular carcinoma(HCC)patients while the underlying mechanism of metastasis remains elusive.In our study,procollagen-lysine,2-oxoglutarate 5-dioxygenase 2(PLOD2)was shown to be involved in the process of metastasis in HCC.Methods:The Cancer Genome Atlas(TCGA)database and HCC tissue microarrays were used to evaluate the expression of genes.In vitro migration,invasion,in vivo subcutaneous tumor model and in vivo lung metastasis assays were used to determine the role of PLOD2 in tumor growth and metastasis in HCC.RNA sequencing and gene set enrichment analysis were performed to uncover the downstream factor of PLOD2 in HCC cells.A luciferase reporter assay was performed to evaluate the interaction between PLOD2 and interferon regulatory factor 5(IRF5).Results:The expression of PLOD2 in HCC tissues was higher than that in adjacent tissues,and increased PLOD2 expression was often found in advanced tumors and was correlated with poor prognosis in HCC patients.In vitro experiments,knockdown of PLOD2 reduced the migration and invasion of human HCC cells.Loss of PLOD2 suppressed human HCC growth and metastasis in a subcutaneous tumor model and a lung metastasis model.Baculoviral IAP repeat containing 3(BIRC3)was proven to be the downstream factor of PLOD2 in human HCC cells.In addition,PLOD2 was transcriptionally regulated by IRF5 in HCC cells.Conclusions:High expression of PLOD2 was regulated by IRF5,which was correlated with the poor survival of HCC patients.PLOD2 enhanced HCC metastasis via BIRC3,suggesting that PLOD2 might be a valuable prognostic biomarker for HCC treatment. | Keren Li Yi Niu Kai Li Chengrui Zhong Zhiyu Qiu Yichuan Yuan Yunxing Shi Zhu Lin Zhenkun Huang Dinglan Zuo Yunfei Yuan Binkui Li | 2023 | Journal of Clinical and Translational Hepatology2023，11，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员